LumaCina Announces Leadership Transition with Gary Bird as CEO

LumaCina, a global supplier and marketer of sterile injectable pharmaceutical products and a Bridgewest Group portfolio company, announced the appointment of Gary Bird as Chief Executive Officer.

Bird was appointed by Executive Chair Mark Crotty, who will continue to lead LumaCina's long-term strategy, overseeing the company's platform development and guiding its next phase of expansion in close partnership with the incoming CEO.

Bird joins LumaCina at a pivotal stage in its evolution as it expands its portfolio, while strengthening strategic partnerships and broadening its presence across Australia and international markets.

Bird brings more than three decades of leadership experience across the Australian pharmaceutical industry, with deep expertise in commercial strategy, market expansion and partnership-led growth. Over the past 13 years, he has led and represented companies including Orion Pharma, Medreich and Meda, working across pharmaceutical distribution, contract manufacturing, specialty medicines and consumer healthcare.